目的:为了解决导管原位癌伴微浸润(DCIS-MI)的腋窝淋巴结分期问题,我们回顾性评估了一组DCIS-MI术后患者的腋窝淋巴结转移率(ALNM).通过分析这些数据,我们旨在产生临床相关的见解,为该患者人群的治疗决策提供信息.
方法:在PubMed上进行了系统搜索,WebofScience,Embase,科克伦图书馆,CNKI,万方数据库,擦拭,和中国生物医学文献数据库,以识别任何语言的相关出版物。所有分析均使用Stata16.0软件进行。
结果:在涉及8279名患者的28项研究中,汇总分析显示,DCIS-MI患者的ALNM率为8%(95%CI,7%~10%).此外,腋窝淋巴结大转移率,微转移,DCIS-MI患者的ITC为2%(95%CI,2%至3%),3%(95%CI,2%至4%),和2%(95%CI,1%至3%),分别。此外,13项研究调查了非前哨淋巴结(Non-SLN)转移率,共包括1236例DCIS-MI病例。合并分析确定DCIS-MI患者的非SLN转移率为33%(95%CI,14%至55%)。
结论:SLNB用于DCIS-MI患者是合理的,可以为全身治疗决策提供新的治疗依据。
OBJECTIVE: To address the question of axillary lymph node staging in ductal carcinoma in situ with microinvasion (DCIS-MI), we retrospectively evaluated axillary lymph nodes metastasis (ALNM) rate in a cohort of postsurgical DCIS-MI patients. By analyzing these data, we aimed to generate clinically relevant insights to inform treatment decision-making for this patient population.
METHODS: A systematic search was conducted on PubMed, Web of Science, Embase, The Cochrane Library, CNKI, Wanfang Database, Wipe, and
China Biomedical Literature Database to identify relevant publications in any language. All the analyses were performed using Stata 16.0 software.
RESULTS: Among the 28 studies involving 8279 patients, the pooled analysis revealed an ALNM rate of 8% (95% CI, 7% to 10%) in patients with DCIS-MI. Furthermore, the rates of axillary lymph node macrometastasis, micrometastasis, and ITC in patients with DCIS-MI were 2% (95% CI, 2% to 3%), 3% (95% CI, 2% to 4%), and 2% (95% CI, 1% to 3%), respectively. Moreover, 13 studies investigated the non-sentinel lymph node (Non-SLN) metastasis rate, encompassing a total of 1236 DCIS-MI cases. The pooled analysis identified a Non-SLN metastasis rate of 33% (95% CI, 14% to 55%) in patients with DCIS-MI.
CONCLUSIONS: The SLNB for patients with DCIS-MI is justifiable and could provide a novel therapeutic basis for systemic treatment decisions.